Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.
Type:
Grant
Filed:
March 15, 2019
Date of Patent:
August 24, 2021
Assignee:
Five Prime Therapeutics, Inc.
Inventors:
Thomas Brennan, David Bellovin, David Busha, Barbara Sennino
Abstract: A method of obtaining a population of cells enriched in human polymorphonuclear myeloid derived suppressor cells (PMN-MDSCs) comprises isolating from a cell suspension those cells which express LOX-1 to provide a population of cells enriched with PMN-MDSCs. A method of monitoring the population of LOX-1+ cells in a cell-containing biological sample is useful for determining the efficacy of treatment or the metastasis or increasing progression of cancer. Other cell isolation and diagnostic methods are also described.
Type:
Grant
Filed:
May 31, 2016
Date of Patent:
July 27, 2021
Assignee:
The Wistar Institute of Anatomy and Biology
Inventors:
Dmitry I. Gabrilovich, Thomas C. Condamine
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Grant
Filed:
September 10, 2020
Date of Patent:
July 20, 2021
Assignee:
IMMATICS BIOTECHNOLOGIES GMBH
Inventors:
Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
Abstract: The present invention relates to a composition for treating prostate cancer and, more specifically, to a composition for treating prostate cancer, which contains a peptide derived from telomerase and is effective in inhibiting growth and metastasis of prostate cancer cells. In addition, the present invention provides a composition and method for treating prostate cancer, wherein, when prostate cancer is treated, docetaxel and the peptide derived from telomerase are co-administered, thereby having a synergetic therapeutic effect compared with administration alone. Particularly, the present invention provides a treatment method useful for patients who do not have a sufficient anticancer effect merely through administration of docetaxel alone and patients who have hormone resistance.
Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 as well as the interaction of CTLA4 with CD86 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.
Type:
Grant
Filed:
May 25, 2018
Date of Patent:
June 15, 2021
Assignee:
Leidos, Inc.
Inventors:
Gabriel M. Gutierrez, Vinayaka Kotraiah, Timothy W. Phares, James Pannucci
Abstract: Provided herein is technology relating to cancer treatment and prevention and particularly, but not exclusively, to compositions and methods related to therapies for prostate cancer.
Abstract: The present invention relates to novel tumor-associated antigens, which elicit independently from a presentation via MHC a CD8-positive T-cell response. GM-CSF-Receptor alpha chain (CSF2RA) and Tyrosinase-related protein 2 (TRP-2) were found to be targets of CD8-positive T-cell clones which could detect the proteins on the surface of HLA I negative melanoma cells. Thus, the invention provides proteins, protein fragments and polypeptides of the novel antigens for use in medicine, for example for the treatment, diagnosis and prevention of a tumor disease. Furthermore provided are nucleic acids expressing the antigens of the invention, binding agents specific for the antigens of the invention, such as T-cell receptor chains and isolated T cells which are reactive against the antigens of the invention or which express the T-cell receptors of the invention.
Type:
Grant
Filed:
November 30, 2017
Date of Patent:
April 27, 2021
Assignee:
BioNTech RNA Pharmaceuticals GmbH
Inventors:
Dirk Schadendorf, Annette Paschen, Silke Lübcke, Martina Fatho, Daniela Eberts, Hakim Echchannaoui, Volker Lennerz, Catherine Woelfel, Thomas Woelfel
Abstract: This invention provides a method that combines a checkpoint inhibitor and a glucocorticoid receptor modulator to treat cancer, e.g., a checkpoint inhibitor sensitive cancer.
Abstract: The present invention relates to the use as a biomarker of the active form of a human caspase protein, preferably the human caspase-4 or caspase-1, or of the active form of the protein encoded by an orthologue gene of the human caspase protein, preferably by an orthologue gene of the human caspase-4, for example the murine caspase-11 protein, in a method of diagnosis and/or prognosis and/or of monitoring the progression of a tumor, particularly lung cancer.
Abstract: Antibodies, compositions, systems, and methods for detecting C4.4a, for example immunohistochemistry methods for detecting C4.4a using a C4.4a antibody. The antibody may be obtained by immunizing a host with a C4.4a protein such as a peptide downstream of the signal peptide. The antibodies may be adapted to detect the uPAR-like domain 1 and uPAR-like domain 2. Also featured are methods for diagnosing C4.4a-associated tumors using C4.4a antibodies disclosed herein.
Type:
Grant
Filed:
October 12, 2017
Date of Patent:
March 16, 2021
Assignee:
Ventana Medical Systems, Inc.
Inventors:
Fernando Jose Rebelo do Couto, Zhiming Liao, Yifei Zhu
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Grant
Filed:
June 29, 2020
Date of Patent:
March 2, 2021
Assignee:
IMMATICS BIOTECHNOLOGIES GMBH
Inventors:
Andrea Mahr, Toni Weinschenk, Anita Wiebe, Oliver Schoor, Jens Fritsche, Harpreet Singh
Abstract: CD47+ disease cells, such as CD47+ cancer cells, are treated with an agent that blocks signalling via the SIRP?/CD47 axis. The agent is a human SIRP? fusion protein that displays negligible CD47 agonism and negligible red blood cell binding. The fusion protein comprises an IgV domain from variant 2 of human SIRP?, and an Fc having effector function. The IgV domain binds human CD47 with an affinity that is at least five fold greater than the affinity of the entire extracellular region of human SIRP?. The fusion protein is at least 5 fold more potent than a counterpart lacking effector function.
Type:
Grant
Filed:
April 25, 2018
Date of Patent:
February 2, 2021
Assignee:
TRILLIUM THERAPEUTICS INC.
Inventors:
Robert Adam Uger, Penka Slavtcheva Slavova-Petrova, Xinli Pang
Abstract: The invention relates to modulating the SIRP?-CD47 interaction in order to treat hematological cancer and compounds therefor. In some embodiments, there is provided methods and uses of SIRP? polypeptides, fragments and fusion proteins for treating hematological cancer, preferably human acute myeloid leukemia.
Type:
Grant
Filed:
May 14, 2010
Date of Patent:
February 2, 2021
Assignees:
UNIVERSITY HEALTH NETWORK, THE HOSPITAL FOR SICK CHILDREN
Inventors:
Jean C. Y. Wang, John Dick, Jayne Danska, Liqing Jin, Alexandre Theocharides, Sujeetha Rajakumar
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Grant
Filed:
June 29, 2020
Date of Patent:
January 26, 2021
Assignee:
IMMATICS BIOTECHNOLOGIES GMBH
Inventors:
Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
Abstract: The technology described herein relates to methods of detecting circulating tumor cells (CTCs), e.g. by detecting changes in the expression of certain CTC marker genes. Aberrant expression of CTC marker genes, e.g. changes in expression indicative of CTCs can also be targeted in order to treat cancer.
Type:
Grant
Filed:
December 18, 2014
Date of Patent:
January 26, 2021
Assignee:
THE GENERAL HOSPITAL CORPORATION
Inventors:
David T. Ting, Daniel A. Haber, Shyamala Maheswaran
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Grant
Filed:
May 29, 2020
Date of Patent:
January 26, 2021
Assignee:
IMMATICS BIOTECHNOLOGIES GMBH
Inventors:
Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
Abstract: The present invention relates to the treatment of breast cancer, more particularly triple negative breast cancer (TNBC), with the use of an inhibitor of Interleukin 1 Receptor Associated Kinase 1 (IRAK1) such as ginsenosides. It also relates to a method for aiding in categorising or determining prognosis in a breast cancer patient or in selecting a therapeutic strategy comprising assessing the level of IRAK1 nucleic acid, protein or activity in a sample and, in some aspects, further assessing the paclitaxel resistance status of the patient and if the patient is resistant to paclitaxel therapy, treating the patient with an inhibitor of IRAK1 activity. In addition, a screening method for identifying a compound useful for treating breast cancer comprises determining the effect of a test compound on IRAK1 nucleic acid, protein or activity level and selecting a compound that reduces said level.
Type:
Grant
Filed:
October 24, 2016
Date of Patent:
January 5, 2021
Assignee:
Agency for Science, Technology and Research
Abstract: A method for distinguishing prostate cancer from prostatic hypertrophy using the method for analyzing PSA and an analysis kit of PSA are provided. An object of the present invention can be solved by being brought into contact a lectin having an affinity for p-N-acetylgalactosamine residues and/or a lectin having an affinity for fucose a(I, 2) galactose residues with a sample possibly containing PSA, to determine an amount of PSA having an affinity for the lectin. A method for distinguishing prostate cancer from prostatic hypertrophy can be provided by this method.
Abstract: Methods for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising an NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.
Type:
Grant
Filed:
December 18, 2009
Date of Patent:
December 15, 2020
Assignee:
Dana-Farber Cancer Institute, Inc.
Inventors:
Glenn Dranoff, Matthew Vanneman, Gordon Freeman
Abstract: This invention relates to methods of inducing differential stress resistance in a subject with cancer by starving the subject for a short term, administering a cell growth inhibitor to the subject, or reducing the caloric or glucose intake by the subject. The induced differential stress resistance results in improved resistance to cytotoxicity in normal cells, which, in turn, reduces cytotoxic side-effects due to chemotherapy, as well as improved effectiveness of chemotherapeutic agents.